ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pain

BlurryMe / shutterstock.com

The Prevention & Management of Medication-Related Osteonecrosis of the Jaw

Pooja Gangwani, DDS, MPH  |  March 15, 2021

Medication-related osteonecrosis of the jaw (MRONJ) is a con­dition that manifests as exposed, necrotic and non-healing jaw bone in patients who have been treated with bisphosphonates, denosumab, chemotherapeutic agents, anti-angiogenic drugs, tyrosine kinase inhibitors, thalidomide and steroids.1-4 These medications are admin­istered via intravenous, subcutaneous and oral routes to manage osteopenia; osteoporosis; hypercalcemia of malignancy; bone…

Filed under:Conditions Tagged with:bisphosphonatesbone mineral density (BMD)Osteonecrosis

Upadacitnib for RA: Researchers Compared Upadacitinib with Placebo & Adalimumab in Patients with RA & an Inadequate Response to Methotrexate

Vanessa Caceres  |  March 9, 2021

In phase 3 clinical trial, upadacitnib proved superior to placebo and adalimumab in improving the signs and symptoms of RA in patients on stable background methotrexate.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2020ACR Convergence 2020 – RAadalimumabjakinibupadacitinib

Diet, Microbes & Inflammation: Unique Microbial Genetic Strains in Inflammatory Disease, Plus a Possible Arthritis Diet

Susan Bernstein  |  March 4, 2021

Experts at ACR Convergence 2020 addressed how diet & the body’s microbiome affect chronic diseases.

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2020Dietgut microbiotainflammationMicrobiome

Myositis & the Heart: New Perspectives on the Pathogenesis & Management of Cardiac Involvement in Myositis

Carina Stanton  |  February 18, 2021

Experts discuss the diagnosis and treatment of myositis-related cardiovascular disease.

Filed under:ACR ConvergenceConditionsMeeting ReportsMyositis Tagged with:ACR Convergence 2020cardiovascularheartHeart Diseasemyocarditismyositis

Study Finds NSAIDs Raise Heart Disease Risk in Osteoarthritis Patients

Susan Bernstein  |  February 16, 2021

In a controlled, large-cohort, longi­tudinal study from Canada, Atiquazzaman et al. found that use of non-steroidal anti-inflammatory drugs (NSAIDs) substantially contributes to increased cardiovascular disease risk among people with osteoarthritis (OA).1  This is the first study to evaluate the mediating role that NSAIDs play in the association between OA and cardiovascular disease (CVD), and the…

Filed under:ConditionsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:Cardiovascular diseaseNonsteroidal anti-inflammatory drugs (NSAIDs)

Case Report: Drug-Induced Lupus & ANCA-Associated Vasculitis Overlap

Mohammad A. Ursani, MD, RhMSUS, Ojas Naik, MD, Rohaan Khan & William F. Glass II, MD, PhD  |  February 16, 2021

Drug-induced lupus erythe­matosus and ANCA-associated vasculitis (AAV) are both autoimmune conditions associated with the use of hydralazine, a commonly prescribed drug for hypertension and congestive heart failure. Although the pathogenesis is unknown, it is believed that hydralazine alters neutrophil and lymphocyte function and promotes exposure of antigens, leading to the development of anti-neutrophil antibodies (ANCA)…

Filed under:ConditionsSystemic Lupus ErythematosusVasculitis Tagged with:ANCA-Associated Vasculitiscase reporthydralazine

Updated Clinical Practice Guidelines for Lyme Disease, Lyme Arthritis

Elizabeth Hofheinz, MPH, MEd  |  February 16, 2021

A team of healthcare practitioners and researchers, spearheaded by the Infectious Diseases Society of America (IDSA), the American Academy of Neurology (AAN) and the ACR, has developed updated evidence-based clinical practice guidelines for the prevention, diagnosis and treatment of Lyme disease. The 2020 guidelines cover a wide variety of Lyme disease manifestations, including Lyme arthritis. Linda…

Filed under:Conditions Tagged with:GuidelinesLyme arthritisLyme Disease

The ARP Revises Its Fundamentals of Rheumatology Course

Hiral Master, PT, PhD, MPH, Teresa J. Brady, PhD, Aileen Ledingham, PT, MS, PhD, & Carole Dodge, OT, CHT, on behalf of the ARP eLearning Subcommittee  |  February 16, 2021

The ARP’s revised Fundamentals of Rheumatology Course (FRC) will soon be released on the ACR website. The course was revamped by interdisciplinary rheuma­tology professionals emphasizing an inter-professional approach to patient care. It is intended to reach a broad audience, including nurses, occupational therapists, pharmacists, physical therapists, psychologists and social workers to name a few. However,…

Filed under:Education & Training Tagged with:Association of Rheumatology Professionals (ARP)

European Commission Approves Upadacitinib for Psoriatic Arthritis & Ankylosing Spondylitis

Michele B. Kaufman, PharmD, BCGP  |  February 4, 2021

In January, upadacitinib was approved for use in Europe as a 15 mg, once-daily dose to treat patients with psoriatic arthritis and ankylosing spondylitis.

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:Ankylosing SpondylitisEuropean Unionpsoriatic arthritisupadacitinib

Reproductive Health, Beyond the Guidelines: Rheumatologists Must Think About Patients’ Psychosocial Needs

Mary Beth Nierengarten  |  January 25, 2021

Experts discuss how rheumatologists must consider the psychosocial aspect of care in the decision-making process for women when addressing their reproductive health needs, in addition to medication safety.

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2020Association of Rheumatology Professionals (ARP)biopsychosocialpatient carepregnancypsychosocial

  • « Previous Page
  • 1
  • …
  • 71
  • 72
  • 73
  • 74
  • 75
  • …
  • 247
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences